Replies to post #167835 on Biotech Values

[stockbettor]

NVO CEO's take on when oral insulin and GLP might be on the market (still years away):

Sorensen hopes to stay around long enough to see the company well on the way to the next stage of technological breakthrough - oral pills, rather than injections, for delivering insulin and so-called GLP-1 medicines like Victoza.

He thinks a GLP-1 pill could hit the market in five years, with a 50/50 chance of an insulin tablet in 6-8 years time.

Novo is trailing Israel's Oramed Pharmaceuticals in clinical testing of an insulin pill, sparking speculation of a possible deal. But Sorensen said this was not on the cards since Novo doubted Oramed's approach.

http://in.reuters.com/article/2013/11/05/us-novonordisk-ceo-idINBRE9A40I220131105?feedType=RSS&feedName=health&utm_source=dlvr.it&utm_medium=twitter&dlvrit=309303

[DewDiligence]

ORMP finished down 4% today; the company PR’d that its phase-2 oral-insulin trial was a success, but many investors are evidently skeptical:

http://blogs.marketwatch.com/health-exchange/2014/01/30/orameds-oral-insulin-tests-are-positive-but-investors-are-skittish/

There is ample reason to be skeptical insofar as the company’s PR furnished no clinical data (http://finance.yahoo.com/news/oramed-announces-successful-fda-phase-090000076.html ).